Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Phase I study of IOA-244 in follicular lymphoma

Carmelo Carlo-Stella • 11 Jun 2022
EHA 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma IOA-244

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, comments on the preliminary findings of a Phase I study evaluating IOA-244, a PI3Kδ inhibitor, in patients with follicular lymphoma (FL) (NCT04328844). Prof. Carlo-Stella explains that this combination appears to be well-tolerated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Carmelo Carlo-Stella

2:21
Important practical considerations for the use of glofitamab for DLBCL
Carmelo Carlo-Stella • 20 Oct 2023
5:30
Glofitamab in R/R DLBCL: updated safety and efficacy data
Carmelo Carlo-Stella • 20 Oct 2023
7:13
Efficacy and safety of glofitamab for patients with Richter’s transformation
Carmelo Carlo-Stella • 15 Jun 2023
2:33
Glofitamab as a single agent in heavily pretreated patients with DLBCL
Carmelo Carlo-Stella • 15 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals